• 四川大學(xué)華西醫(yī)院泌尿外科,四川成都 610041;

引用本文： 柳良仁,魏強(qiáng). 良性前列腺增生癥與組織炎癥. 華西醫(yī)學(xué), 2009, 24(5): 1314-1316. doi: 復(fù)制

1. Berry S J, Coffey D S, Walsh P C, et alThe development of human benign prostatic hyperplasia with age[J]. J Urol,1984,132（3）:474-479.
2. Nickel J C, Downey J, Hunter D, et al Prevalence of prostatitislike symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol,2001,165(3):842-845.
3. Collins M M, Meigs J B, Barry M J, et al. Prevalence and correlates of prostatitis in the health professionals followup study cohort[J]. J Urol,2002,167: 1363-1366.
4. St Sauver J L, Jacobson D J, McGree M E, et al. Longitudinal association between prostatitis and development of benign prostatic hyperplasia[J]. Urology,2008,71(3):475-479.
5. Nickel J C, Roehrborn C G, O’Leary M P, et al. The relationship between symptoms of prostatitis and histologic inflammation: Examination of baseline data from the REDUCE chemoprevention trial[J]. J Urol,2007,178(3):896-901.
6. Roehrborn C G. Definition of atrisk patients: baseline variables[J]. BJU Int,2006,97 Suppl 2:711;discussion:21-22.
7. Kramer G, Steiner G E, Handisurya A, et al. Increased expression of lymphocytederived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation[J]. Prostate,2002,52(1):43-58.
8. Steiner G E, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue[J]. Lab Invest,2003,83(8):1131-1146.
9. Lee K L, Peehl D M. Molecular and cellular pathogenesis of benign prostatic hyperplasia[J]. J Urol,2004,172:1784-1791.
10. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia ?[J]Curr Opin Urol,2006,16(1):25-29.
11. Wang W, Bergh A, Damber J E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase2, Bcl2, and cell proliferation in the glandular epithelium[J]. Prostate,2004,61(1):60-72.
12. Steiner G, Kramer G, Stix U, et al. Characterization of mechanism behind the process of chronic prostatic inflammation and its role in prostatic growth[J]. Eur Urol,2004,Suppl 3(2):203.
13. Yi F X (易發(fā)現(xiàn)), Wei Q, Li H, et al Risk factors for prostatic inflammation extent and infection in benign prostatic hyperplasia[J]. Asian J Androl,2006,8(5):621-627.
14. Knig J E, Senge T, Allhoff E P, et al Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer[J]. Prostate,2004,58:121-129.
15. Kramer G, Dieter M, Hrachowitz K, et al. Benign prostatic hyperplasia specimens derived from patients after urinary retention show significantly more prostate glands with upregulation of HLADR and loss of CD38 than those derived from patients without urinath retention[J]. Eur Urol Suppl,2006,5(2):120.
16. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase 2 and prostate carcinogenesis[J]. Cancer Lett,2003,191(2):125-135.
17. Nickel J C. The use of α1adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia[J]. Urology,2003,62(3 Suppl 1):34-41.
18. 王龍,王維佳,楊金瑞.良性前列腺增生合并前列腺炎的研究進(jìn)展[J].國(guó)際泌尿系統(tǒng)雜志,2006,26(2):152-155.
19. Ho C K, Nanda J, Chapman K E, et al. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen[J]. J Endocrinol,2008,197(3):483-491.
20. Prins G S, Korach K S. The role of estrogens and estrogen receptors in normal prostate growth and disease[J]. Steroids,2008,73(3):233-244.
21. Stone N N, Fair W R, Fishman J. Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia[J]. Prostate,1986,9(4):311-318.
22. Smith P, Rhodes N P, Ke Y, et al. Upregulation of estrogen and androgen receptors modulate expression of FGF2 and FGF7 in human, culutured, prostatic stromal cells exposed to high concentrations of estradiol[J]. Prostate Cancer Prostatic Dis,2002,5(2):105-111.
23. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: agerelated tissueremodeling[J]. Exp Gerontol,2005,40(3):121-128.
24. Di Silverio F, Bosman C, Salvatori M, et al Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)[J]. Eur Urol,2005,47(1):72-79.
25. Re G, Badino P, Odore R, et al Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats[J]. Pharmacol Res,2001,44(2):141-147.
  1. 1. Berry S J, Coffey D S, Walsh P C, et alThe development of human benign prostatic hyperplasia with age[J]. J Urol,1984,132（3）:474-479.
  2. 2. Nickel J C, Downey J, Hunter D, et al Prevalence of prostatitislike symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol,2001,165(3):842-845.
  3. 3. Collins M M, Meigs J B, Barry M J, et al. Prevalence and correlates of prostatitis in the health professionals followup study cohort[J]. J Urol,2002,167: 1363-1366.
  4. 4. St Sauver J L, Jacobson D J, McGree M E, et al. Longitudinal association between prostatitis and development of benign prostatic hyperplasia[J]. Urology,2008,71(3):475-479.
  5. 5. Nickel J C, Roehrborn C G, O’Leary M P, et al. The relationship between symptoms of prostatitis and histologic inflammation: Examination of baseline data from the REDUCE chemoprevention trial[J]. J Urol,2007,178(3):896-901.
  6. 6. Roehrborn C G. Definition of atrisk patients: baseline variables[J]. BJU Int,2006,97 Suppl 2:711;discussion:21-22.
  7. 7. Kramer G, Steiner G E, Handisurya A, et al. Increased expression of lymphocytederived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation[J]. Prostate,2002,52(1):43-58.
  8. 8. Steiner G E, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue[J]. Lab Invest,2003,83(8):1131-1146.
  9. 9. Lee K L, Peehl D M. Molecular and cellular pathogenesis of benign prostatic hyperplasia[J]. J Urol,2004,172:1784-1791.
  10. 10. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia ?[J]Curr Opin Urol,2006,16(1):25-29.
  11. 11. Wang W, Bergh A, Damber J E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase2, Bcl2, and cell proliferation in the glandular epithelium[J]. Prostate,2004,61(1):60-72.
  12. 12. Steiner G, Kramer G, Stix U, et al. Characterization of mechanism behind the process of chronic prostatic inflammation and its role in prostatic growth[J]. Eur Urol,2004,Suppl 3(2):203.
  13. 13. Yi F X (易發(fā)現(xiàn)), Wei Q, Li H, et al Risk factors for prostatic inflammation extent and infection in benign prostatic hyperplasia[J]. Asian J Androl,2006,8(5):621-627.
  14. 14. Knig J E, Senge T, Allhoff E P, et al Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer[J]. Prostate,2004,58:121-129.
  15. 15. Kramer G, Dieter M, Hrachowitz K, et al. Benign prostatic hyperplasia specimens derived from patients after urinary retention show significantly more prostate glands with upregulation of HLADR and loss of CD38 than those derived from patients without urinath retention[J]. Eur Urol Suppl,2006,5(2):120.
  16. 16. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase 2 and prostate carcinogenesis[J]. Cancer Lett,2003,191(2):125-135.
  17. 17. Nickel J C. The use of α1adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia[J]. Urology,2003,62(3 Suppl 1):34-41.
  18. 18. 王龍,王維佳,楊金瑞.良性前列腺增生合并前列腺炎的研究進(jìn)展[J].國(guó)際泌尿系統(tǒng)雜志,2006,26(2):152-155.
  19. 19. Ho C K, Nanda J, Chapman K E, et al. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen[J]. J Endocrinol,2008,197(3):483-491.
  20. 20. Prins G S, Korach K S. The role of estrogens and estrogen receptors in normal prostate growth and disease[J]. Steroids,2008,73(3):233-244.
  21. 21. Stone N N, Fair W R, Fishman J. Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia[J]. Prostate,1986,9(4):311-318.
  22. 22. Smith P, Rhodes N P, Ke Y, et al. Upregulation of estrogen and androgen receptors modulate expression of FGF2 and FGF7 in human, culutured, prostatic stromal cells exposed to high concentrations of estradiol[J]. Prostate Cancer Prostatic Dis,2002,5(2):105-111.
  23. 23. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: agerelated tissueremodeling[J]. Exp Gerontol,2005,40(3):121-128.
  24. 24. Di Silverio F, Bosman C, Salvatori M, et al Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)[J]. Eur Urol,2005,47(1):72-79.
  25. 25. Re G, Badino P, Odore R, et al Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats[J]. Pharmacol Res,2001,44(2):141-147.